High-purity active pharmaceutical ingredients manufactured under rigorous ICH Q7 protocols for research, clinical development, and commercial formulation in the Region of Coimbra.
Bridging Advanced Chemical Synthesis in China with Portugal’s Academic and Clinical Oncology Capital
The city of Coimbra stands as the historical and technological heart of medical innovation in Portugal. Home to the legendary University of Coimbra (Universidade de Coimbra), the Centro Hospitalar e Universitário de Coimbra (CHUC), and cutting-edge translational research centers such as the iNEM (Institute for Biomedical Imaging and Life Sciences) and nearby Biocant Park in Cantanhede, the region drives Europe's progress in targeted cancer therapies, genomic medicine, and advanced pharmacology.
As the demand for precision antineoplastic agents rises across the European Union, securing a reliable, fully audited, and high-purity supply chain for active pharmaceutical ingredients (APIs) and advanced chemical intermediates has become a critical strategic objective for life science entities operating within the Coimbra ecosystem. Hangzhou Jeci Biochem Technology Co., Ltd. serves as a premier manufacturing and exporting partner, engineering robust chemical pipelines that connect high-capacity Industry 4.0 production facilities with the stringent regulatory and scientific mandates of the Portuguese oncology sector.
All anticancer APIs, including tyrosine kinase inhibitors (TKIs) and immunomodulators, are isolated with controlled particle size distribution (PSD) and ultra-low elemental impurity thresholds (ICH Q3D).
Complete support for Drug Master Files (DMF), ASMF filings, Certificate of Suitability (CEP), and custom audit documentation required for seamless regulatory clearance in Portugal.
Dedicated logistics frameworks ensuring strict temperature preservation (2°C to 8°C or -20°C ambient controls) for sensitive antineoplastic intermediates shipped directly into Coimbra.
Hangzhou Jeci Biochem Technology Co., Ltd. is strategically located in Hangzhou, Zhejiang Province—one of China’s premier high-tech pharmaceutical and chemical manufacturing corridors. We are dedicated to the scientific synthesis, sales, cooperative R&D, custom manufacturing (CDMO/CMO), and international trade of active pharmaceutical ingredients, advanced chemical intermediates, and specialized bio-molecules.
In China, our organization leverages a formidable collaborative R&D infrastructure. We maintain deep technological integration with leading national drug research institutes and multi-site custom processing plants. Our domestic operations encompass comprehensive product application engineering, technology transfer programs, direct chemical supply, toll manufacturing, and exclusive distribution networks across key biotechnology regions.
Furthermore, our senior technical advisory teams provide specialized quality management system (QMS) certification consulting, assisting international partners in auditing manufacturing sites for compliance with global standards, including ISO 9001:2015, ISO 14001, and cGMP standards.
Our antineoplastic APIs and specialized intermediate portfolios are integral components across several critical industrial and scientific sectors serving the Coimbra region:
We operate modern, fully automated reaction centers capable of scaling intermediate batch processing seamlessly from bench top R&D to multi-ton industrial outputs. Our technical installations feature high-pressure hydrogenation reactors, cryogenic synthesis vessels operating down to -80°C, continuous flow reactors, and industrial-scale preparative HPLC systems.
For our core chemical intermediates, we maximize engineering efficiency to guarantee rapid turnaround times, rigid batch-to-batch consistency, and rigorous control over genotoxic impurities (GTIs), fulfilling all requirements specified by regional pharmaceutical developers in Coimbra and broader European markets.
Innovating Chemical Pathways for Next-Generation Antineoplastic Therapies
The landscape of modern oncology is shifting rapidly from non-specific cytotoxic chemotherapy toward targeted small-molecule inhibitors, immunomodulators, and targeted protein degraders (PROTACs). To serve academic researchers and commercial formulators in Coimbra, Hangzhou Jeci Biochem continuously upgrades its synthetic chemistry pathways and technical roadmap:
Our facility specializes in high-yield synthetic routes for second and third-generation TKIs, including Dasatinib Monohydrate (CAS 863127-77-9), Cabozantinib (CAS 849217-68-1), and Ceritinib (CAS 1032900-25-6). By utilizing advanced catalytic cross-coupling techniques (such as Buchwald-Hartwig amination and Suzuki-Miyaura coupling), we minimize residual heavy metal contamination to single-digit ppm levels.
To enhance process safety and chemical yield for highly energetic or hazardous reactions (such as nitrations and halogenations), we have integrated continuous flow reactors. This operational paradigm ensures precise thermal control, reduced side-reactions, and consistent polymorph generation for critical raw materials like Ibrutinib (CAS 936563-96-1) and Axitinib (CAS 319460-85-0).
Oncology APIs often rely on absolute stereochemical configuration for therapeutic efficacy. Utilizing enzymatic resolution, chiral chromatography, and asymmetric synthesis, we guarantee stereochemical purity (>99.5% enantiomeric excess) for products requiring delicate spatial arrangements, minimizing off-target metabolic toxicity.
In alignment with European Sustainability Directives and environmental safety standards supported by the Portuguese industrial sector, our manufacturing centers employ solvent recovery systems, bio-catalytic pathways, and reduced water-consumption models, cutting carbon intensity across the entire API manufacturing lifecycle.
Fulfilling Infarmed Safeguards and Expediting EU Customs Integration
Importing active pharmaceutical ingredients into Portugal requires flawless adherence to national regulations overseen by Infarmed (Autoridade Nacional do Medicamento e Produtos de Saúde I.P.) and European Union frameworks established by the EMA. Hangzhou Jeci Biochem provides comprehensive support to demystify complex regulatory barriers for Coimbra-based entities:
We provide extensive technical packages including Certificates of Analysis (CoA), High-Performance Liquid Chromatography (HPLC) spectra, Proton Nuclear Magnetic Resonance (1H-NMR), Mass Spectrometry (MS), Fourier-Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), and Thermogravimetric Analysis (TGA).
Our collaborative manufacturing centers are open to virtual and on-site customer audits. We assist Portuguese biopharmaceutical companies with complete supplier qualification workflows and risk management documentation under ICH Q9 protocols.
With multi-site production redundancies in China, we eliminate single-point supply failures. Raw material reserves for strategic APIs (such as Paclitaxel and Gemcitabine Hydrochloride) are maintained to buffer against global logistics interruptions.
Internationally, Hangzhou Jeci Biochem maintains robust, long-term commercial relationships across established biopharmaceutical markets including Portugal, India, Southeast Asia, South Korea, Japan, and North America. We deliver complete lifecycle support—from early-stage market analysis and regulatory submission to channel expansion and dedicated customer account management. Furthermore, we actively provide product registration, market access consulting, and sales distribution expansion services for overseas enterprises seeking entry into China’s rapidly growing pharmaceutical market.
Explore our extensive catalog of high-purity chemical intermediates and active ingredients optimized for export to Coimbra and global markets.
Technical and Logistics Insights for Procurement Officers & Researchers in Coimbra
Secure your supply chain with clinical-grade APIs, comprehensive DMF technical support, and competitive factory-direct pricing for the Coimbra market.
Send Inquiry Now
SJ medical